Selected articles
Articles for label Protivánková Markéta are displayed.. Show all articles
Treatment of metastatic HER2 positive breast cancer in young patient with very advanced disease – case report
04/2019 MUDr. Markéta Protivánková; MUDr. Dagmar Brančíková, Ph.D.; MUDr. Jiří Vašina
Although the percentage of patients diagnosed in the early stage of the disease is increasing after the introduction of breast cancer screening, a large group of patients still have metastatic breast cancer. Advanced HER2 positive breast cancer has been therapeutically difficult to treat with adverse prognosis until the introduction of targeted anti-HER2 therapy, and its therapy has been complicated by a number of possible side effects and considerable toxicity. Our case report describes a case of a 42-year-old patient who had HER2 positive breast cancer diagnosed at a very advanced stage of the disease. After the use of dual-block treatment with concomitant administration of trastuzumab and pertuzumab, a high-quality and long-term response of the disease was achieved in which the quality of life of the patient significantly increased. At the same time, this treatment was very well tolerated.
ENTIRE ARTICLE
Although the percentage of patients diagnosed in the early stage of the disease is increasing after the introduction of breast cancer screening, a large group of patients still have metastatic breast cancer. Advanced HER2 positive breast cancer has been therapeutically difficult to treat with adverse prognosis until the introduction of targeted anti-HER2 therapy, and its therapy has been complicated by a number of possible side effects and considerable toxicity. Our case report describes a case of a 42-year-old patient who had HER2 positive breast cancer diagnosed at a very advanced stage of the disease. After the use of dual-block treatment with concomitant administration of trastuzumab and pertuzumab, a high-quality and long-term response of the disease was achieved in which the quality of life of the patient significantly increased. At the same time, this treatment was very well tolerated.
Breast cancer immunotherapy – a promising way?
04/2019 MUDr. Dagmar Brančíková, Ph.D.; MUDr. Markéta Protivánková
Immunotherapy is an emerging new modality in the treatment of many tumors. In the treatment of breast carcinomas, there is already the first experience with this treatment, which gradually defines the subgroups of patients and stages of breast malignancies that receive the highest profits from immunotherapy alone or in combinations with chemotherapy and target therapy. We present a review of the literature on clinical (age, weight, gender) and laboratory parameters that predict the response to immunotherapy and an overview of suitable combinations with chemotherapy or targeted agents in the treatment of metastatic breast cancer. Monotherapy checkpoint inhibitors do not yet appear to be effective but combinations atezolizumab or pembrolizumab with nab-paclitaxel and eribulin mesylate in neoadjuvant and in the first line of palliation are very promising in the treatment of triple-negative breast cancer locally advanced. So far, in the treatment of HER (epidermal growth factor receptor) positive tumors and ER (estrogen receptor) positive, a subset of patients with significant immunotherapy benefit cannot be unequivocally established.
ENTIRE ARTICLE
Immunotherapy is an emerging new modality in the treatment of many tumors. In the treatment of breast carcinomas, there is already the first experience with this treatment, which gradually defines the subgroups of patients and stages of breast malignancies that receive the highest profits from immunotherapy alone or in combinations with chemotherapy and target therapy. We present a review of the literature on clinical (age, weight, gender) and laboratory parameters that predict the response to immunotherapy and an overview of suitable combinations with chemotherapy or targeted agents in the treatment of metastatic breast cancer. Monotherapy checkpoint inhibitors do not yet appear to be effective but combinations atezolizumab or pembrolizumab with nab-paclitaxel and eribulin mesylate in neoadjuvant and in the first line of palliation are very promising in the treatment of triple-negative breast cancer locally advanced. So far, in the treatment of HER (epidermal growth factor receptor) positive tumors and ER (estrogen receptor) positive, a subset of patients with significant immunotherapy benefit cannot be unequivocally established.
Will pertuzumab find its place in an neoadjuvant chemotherapy?
04/2018 MUDr. Markéta Protivánková
Neoadjuvant chemotherapy is a systemic treatment, which is given before a local procedure that leads to the removal of the tumor. In the treatment of breast cancer, it is intended especially for the patients in whom we want to achieve the downstaging of the tumor in order to improve its operability and to achieve breast conserving surgery. Although there is currently no longer long-term survival in patients who undergo neoadjuvant chemotherapy, patients who achieve complete pathological remission (pCR) have a better long-term prognosis. In patients with HER2 positive tumors, a significantly higher number of pCR is achieved if trastuzumab is added to neoadjuvant treatment, when dual blockade is added to the combination via simultaneous administration of trastuzumab and pertuzumab with chemotherapy, the pCR almost doubles. For this reason, pertuzumab should be used as a essential component of neoadjuvant chemotherapy in patients with high-risk HER2-positive breast cancer in combination with trastuzumab.
ENTIRE ARTICLE
Neoadjuvant chemotherapy is a systemic treatment, which is given before a local procedure that leads to the removal of the tumor. In the treatment of breast cancer, it is intended especially for the patients in whom we want to achieve the downstaging of the tumor in order to improve its operability and to achieve breast conserving surgery. Although there is currently no longer long-term survival in patients who undergo neoadjuvant chemotherapy, patients who achieve complete pathological remission (pCR) have a better long-term prognosis. In patients with HER2 positive tumors, a significantly higher number of pCR is achieved if trastuzumab is added to neoadjuvant treatment, when dual blockade is added to the combination via simultaneous administration of trastuzumab and pertuzumab with chemotherapy, the pCR almost doubles. For this reason, pertuzumab should be used as a essential component of neoadjuvant chemotherapy in patients with high-risk HER2-positive breast cancer in combination with trastuzumab.
New recommendations for neoadjuvant treatment of HER2‑positive breast cancer patients
04/2017 MUDr. Dagmar Brančíková, Ph.D., MUDr. Markéta Protivánková
Treatment of locally advanced breast cancer with HER2/neu amplification is systemic and consists of chemotherapy and receptor blockade. The neoadjuvant procedure is designed to rapidly reduce tumor mass and operability, despite the misgivings of several studies, the complete remission remains pathological (pCR) is a reliable substitute Time to progression or overall survival. In this paper we present a summary of some experience with chemotherapy regimens and HER2/neu blockers and their potential combinations. The most promising 3-year data from trial NeoSphere show a promising trend to improve progression free survival for the combination of docetaxel/trastuzumab/pertuzumab that increased pCR from 29% to 46%. In all neoadjuvant studies, the group of patients with a hormone-positive disease had less benefit from anti-HER2 blockade and chemotherapy, but this procedure has yet to be verified as the best.
ENTIRE ARTICLE
Treatment of locally advanced breast cancer with HER2/neu amplification is systemic and consists of chemotherapy and receptor blockade. The neoadjuvant procedure is designed to rapidly reduce tumor mass and operability, despite the misgivings of several studies, the complete remission remains pathological (pCR) is a reliable substitute Time to progression or overall survival. In this paper we present a summary of some experience with chemotherapy regimens and HER2/neu blockers and their potential combinations. The most promising 3-year data from trial NeoSphere show a promising trend to improve progression free survival for the combination of docetaxel/trastuzumab/pertuzumab that increased pCR from 29% to 46%. In all neoadjuvant studies, the group of patients with a hormone-positive disease had less benefit from anti-HER2 blockade and chemotherapy, but this procedure has yet to be verified as the best.